Bio-Bridge Science Issues Corporate Update
June 19 2007 - 6:29AM
Business Wire
Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company
engaged in the commercial development of vaccines for the
prevention and treatment of human infectious diseases issues a
corporate update today. The Company�s strategy is to develop its
own vaccines, to establish a vaccine and drug distribution network,
and to acquire promising vaccine-producing and vaccine-related
companies in China to diversify product offerings. Complementary
Acquisition The Company is in discussions with several potential
acquisition targets in China. These targets are primarily vaccine
companies with increasing vaccine sales and stable sales channels.
Other targets include vaccine development and production-related
companies. Our short-term goal is to acquire one of these vaccine
companies, which will increase our product offerings and revenues,
and establish our first sales channel in China. Our goal is to
acquire at least 51% of a target company at a reasonable price. We
will provide further information when an acquisition agreement has
been signed. In-House Vaccine Product Development HIV vaccine: The
pre-clinical studies of our HIV Vaccine on laboratory animals were
completed by the Beijing Institute of Radiation Medicine and showed
encouraging results. After the vaccine samples are produced in our
GMP facility in Beijing, we will submit application for clinical
trials with the SFDA. Second generation of a HPV vaccine (a
polyvalent vaccine): We entered into a cooperative agreement with
the Institute of Basic Medical Sciences at the Chinese Academy of
Medical Sciences, a leading medical research institute in China, to
research and develop a human papillomavirus polyvalent vaccine
using prokaryotic expression system (HPV vaccine). This vaccine is
designed to prevent from infection by human papillomavirus types 6,
11, 16, 18, 31, 45, and 58 and would, if successful, prevent more
types of HPV infection than the current vaccines in the market and
the cost of the production will be significantly lower. Currently
the pre-clinical study of the HPV vaccine is under way. We expect
that the pre-clinical study can be completed in the second half of
2008. Facility Completion Update The electricity project for our
GMP facility in Beijing is in process and the Company expects the
project to be completed in the second half of 2007. We expect at
that time the facility will be fully operational. Dr. Liang Qiao,
Chairman and CEO of Bio-Bridge Science said, "We believe that a
completion of our planned acquisition will enable us to increase
our revenue and build a vaccine and drug distribution network in
China. Also, our association with leading medical research
institutes in China will solidify our research capability as we try
to introduce more potential vaccine products in addition to our
current vaccines in development.� This press release contains
forward-looking statements. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future
events or performance, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
defined in this document and in statements filed from time to time
with the Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether
made by or on behalf of the company, are expressly qualified by
these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition,
the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. Please refer to the Company�s SEC filings for additional
information.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bio Bridge Science Inc (CE) (OTCMarkets): 0 recent articles
More Bio-Bridge Science, Inc. News Articles